A Perspective on Imiquimod Microneedles for Treating Warts.

Tsu-Man Chiu,Min-Hua Chen,Cheng-An J. Lin,Tsai-Ching Hsu,Mohd Yaqub Khan,Ping-Chun Hsu,Nobutaka Hanagata,Chun-Hung Lee

doi:10.3390/pharmaceutics13050607

Abstract

Warts are a common skin problem and are caused by infection with a virus. Warts are currently mainly treated by therapies involving ablating tissue or interrupting cellular division. However, all these existing treatments are either invasive or cause skin pain and tissue destruction. Imiquimod is a synthetic compound that belongs to the imidazoquinolinone family. It has been successfully used as a topical drug to treat external anogenital warts. However, topical imiquimod cream for warts is restricted by low skin permeability, and several side effects such as itching, pain, and erosions occur most frequently following topical treatment. Microneedle technology, a minimally invasive drug delivery system, has the potential to overcome the barrier of the stratum corneum. This technique would also offer a painless treatment choice and provide personalized therapies. In the study, we loaded imiquimod within dissolving microneedles using the molding method. Gelatin was used as a structural material for microneedle formation without adding a crosslinker. To our knowledge, this is the first study of using dissolving microneedles and exploring their utilization with imiquimod for the treatment of warts. First, we added fluorescent dye and trypan blue into the microneedles to evaluate the status of drugs in the microneedles and the degradation property of microneedles made of gelatin, respectively. Here we also prove the strength of the imiquimod microneedles and study their capability to penetrate the skin. The results show no apparent differences in mechanical failure after an additional imiquimod-loaded. Besides, we provide evidence that imiquimod microneedles induce secreted embryonic alkaline phosphatase (SEAP) in the RAW 264.7 macrophages. Gelatin does not affect the imiquimod in microneedles; a similar immune response was affected by the imiquimod alone or imiquimod complexed with gelatin. Our research demonstrates a proof of concept of using imiquimod microneedles for future warts treatment.

Highlights

Warts are a common disease of the skin caused by infection with a virus
Our research aims to demonstrate a proof of concept of using imiquimod microneedles for future warts treatment
The results showed that the weight ratio of 1:2 and 1:2.5 made it easier to prepare microneedles (Figure 1a–d), while made it easier to prepare microneedles (Figure 1a–d), while the the other ratios containing lower water caused the gelatin solutions to be too viscous to other ratios containing lower water caused the gelatin solutions to be too viscous to make make microneedles properly (Figure 1a,b)

Summary

Introduction

Warts are a common disease of the skin caused by infection with a virus. Pharmaceutics 2021, 13, 607 process (podofilox, intralesional or systemic interferon, intralesional Bleomycin, and 5fluorouracil); all these treatments are either invasive or cause skin pain and tissue destruction [2,3]. 1-(2-methyl propyl)-1H-imidazo[4,5-c]quinolin-4-amine (C14 H16 N4 ), is a synthetic compound belonging to the imidazoquinolone family of drugs which is suitable for topical treatment and has been successfully used as a topical immune response modifier for the treatment of external anogenital warts [4]. Once imiquimod is delivered into the epidermal layer of skin, it will lead to antigen-presenting cells’ activation and subsequently lead cells to migrate to local lymph nodes to activate the adaptive immune system [5,6]

Methods

Results

Discussion

Conclusion